Evidence map›Paper›PMID 24976972›Full record

ArticleJournal of thoracic disease2014

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

Michael DeGregorio, Lin Soe, Michael Wolf

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00409188 (A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax®), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00409188 phase3completednot on this map

A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.

TypeinterventionalSponsorEMD SeronoRan2007 to 2015Enrolled1,513ConditionsNon-small Cell Lung CancerArmsTecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Immunomodulatory Nanosystems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Review
  4. [Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019
    Review
  5. Review
  6. Tecemotide: an antigen-specific cancer immunotherapy.Human vaccines & immunotherapeutics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael DeGregorio1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
Lin Soe1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.
Michael Wolf1 University of California, Davis, Department of Internal Medicine, Division of Hematology and Oncology, Sacramento, CA, USA ; 2 El Dorado Hematology and Oncology, Marshall Hospital, Cameron Park, CA, USA ; 3 Department of ImmunoOncology, Merck Serono Research, Merck KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID24976972
PMCPMC4073360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.